샘플 요청 목록

 카트 문의
시장보고서
상품코드
1758033

세계의 담도암 시장

Biliary Tract Cancers
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 282 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 담도암 시장은 2030년까지 7억 7,870만 달러에 달할 전망

2024년에 6억 2,580만 달러로 추정되는 세계의 담도암 시장은 2030년에는 7억 7,870만 달러에 달하며, 분석 기간인 2024-2030년의 CAGR은 3.7%로 성장할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 간내 담관암은 CAGR 3.5%를 기록하며, 분석 기간 종료시에는 4억 4,730만 달러에 달할 것으로 예측됩니다. 간외 담관암 부문의 성장률은 분석 기간에 CAGR 4.3%로 추정됩니다.

미국 시장은 1억 7,050만 달러로 추정, 중국은 CAGR 6.8%로 성장 예측

미국의 담도암 시장은 2024년에 1억 7,050만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2024-2030년의 CAGR을 6.8%로 2030년까지 1억 5,610만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.5%와 2.9%로 예측됩니다. 유럽에서는 독일이 CAGR 2.1%로 성장할 것으로 예측됩니다.

세계의 담도암 시장 - 주요 동향과 촉진요인 정리

담도암이 전 세계에서 의료와 연구의 주목을 받는 이유는 무엇인가?

담관암, 담낭암, 비장암 등 담도암은 전 세계에서 발병률 증가, 진단의 복잡성, 나쁜 예후 등으로 인해 점점 더 많은 관심을 받고 있습니다. 이러한 암은 담관, 담낭 또는 관련 구조물에 발생하며, 진행되기 전까지는 증상이 없는 경우가 많아 조기 발견이 지속적인 과제입니다. 특히 중저소득 국가에서는 인지도가 낮고 검진 프로토콜이 거의 없기 때문에 대부분의 환자는 수술이 불가능하거나 전이된 상태에서 진단을 받습니다. 원발성 경화성 담관염, 간흡충 감염, 만성 담도염, 특정 유전자 돌연변이 등의 위험 요인이 선진국과 신흥 국가 모두에서 유병률 증가에 기여하고 있습니다. 동남아시아 및 라틴아메리카에서는 Opisthorchis viverrini 및 Clonorchis sinensis와 같은 풍토병 기생충 감염이 담관암 발생률 증가와 관련이 있습니다. 한편, 비만, 당뇨병, 대사증후군 증가는 서유럽인의 담낭암 발생에 기여하는 것으로 여겨지고 있습니다. 담도암은 역사적으로 잘 알려지지 않았음에도 불구하고 그 공격적인 특성과 새로운 진단법 및 표적 치료법의 중요한 필요성으로 인해 현재 임상적으로 많은 관심을 받고 있습니다. 담도암의 희귀성과 이질성은 연구 과제가 되고 있으며, 질병 메커니즘과 치료 반응을 이해하기 위해 전 세계 협력 체제를 강화해야 합니다. 암 전문의와 의료 시스템이 이 분야의 시급한 미충족 수요를 인식함에 따라 담도암은 암 치료의 중요한 개발지가 되고 있으며, 보다 강력한 의료, 정책 및 연구 개입이 요구되고 있습니다.

진단과 영상 진단의 발전은 담도암 발견을 어떻게 변화시키고 있는가?

최근 영상 기술, 분자진단 및 바이오마커 연구의 발전으로 담도암의 진단과 특징이 크게 향상되었으나 여전히 과제가 남아있습니다. 기존에는 증상이나 간효소 상승, 초음파나 CT 스캔과 같은 영상 진단에 의존해 진단했으나, 초기 종양에 대한 민감도가 낮은 경우가 많았습니다. 최근에는 조영 MRI, MRCP(자기공명 담관 췌관조영술), PET-CT 스캔과 같은 고해상도 영상 진단법으로 담도를 보다 상세하게 가시화하여 종양의 국소 진단, 병기 진단, 수술 계획을 보다 잘 세울 수 있게 되었으며, ERCP(내시경적 역행성 담관 췌관조영술), EUS(내시경적 초음파)와 같은 내시경적 초음파 음파)와 같은 내시경 기술은 조직 샘플링 기능을 제공하여 진단의 정확도를 향상시킵니다. 액체생검 플랫폼과 차세대 염기서열 분석기(NGS)의 개발은 조기 발견과 돌연변이 프로파일링의 새로운 문을 열어 보다 정확하고 맞춤화된 치료 전략을 가능하게 했으며, CA19-9와 CEA를 포함한 주요 바이오마커는 비특이적이지만 이미지 데이터와 결합하여 질병의 진행을 예측할 수 있습니다. 영상 데이터와 결합하여 질병의 진행을 모니터링하는 데 도움을 주고 있습니다. 또한 순환 종양 DNA(ctDNA), 마이크로 RNA 시그니처, 메틸화 패턴의 탐색은 비침습적 혈액 기반 진단 툴의 발전을 촉진하고 있습니다. 이러한 툴은 생검이 위험하거나 해부학적으로 어려운 경우 특히 유용하며, AI를 활용한 이미지 분석 및 예측 알고리즘도 등장하여 미묘한 이상을 식별하고 진단 지연을 줄일 수 있는 가능성을 제공합니다. 이러한 진단 혁신은 담도암의 발견과 관리 방법을 꾸준히 변화시키고 있으며, 조기 개입과 환자 예후 개선을 위한 길을 열어가고 있지만, 자원이 한정된 환경에서는 접근성과 비용이 여전히 장벽으로 작용하고 있습니다.

담도암의 치료 상황을 바꾸고 있는 치료의 발전은 어떤 것이 있는가?

담도암의 치료 환경은 전신요법, 정밀종양학, 수술기술의 발달로 인해 눈에 띄게 변화하고 있습니다. 역사적으로 담도암의 치료 옵션은 수술과 완화적 화학요법으로 제한되어 있었고, 완치 가능성은 절제술에 국한되어 있었습니다. 그러나 절제 가능한 환자의 비율은 30% 이하이며, 재발률은 여전히 높습니다. 젬시타빈이나 시스플라틴과 같은 표준 화학요법의 효과는 미미하여 보다 개별화된 표적치료제로의 전환을 촉구하고 있습니다. 분자 프로파일링의 출현으로 FGFR2 융합, IDH1 돌연변이, HER2 과발현, MSI 고농도 등 일부 환자에서 실용적인 돌연변이가 확인되어 페미가티닙, 이보시데닙, 트라스투주맙과 같은 표적 치료제의 개발로 이어졌습니다. 면역요법, 특히 펨브롤리주맙과 니볼루맙과 같은 체크포인트 억제제는 MSI가 높거나 PD-L1 양성 종양에 유망하지만, 반응은 다양합니다. 현재 진행 중인 임상시험에서는 내성을 극복하고 반응률을 개선하기 위한 병용 전략이 검토되고 있습니다. 국소 진행성 사례에서는 방사성 색전술, 광역학 치료, 경동맥화학색전술(TACE)과 같은 간 지향성 요법이 점점 더 많이 사용되고 있습니다. 복강경 수술과 로봇 보조 수술의 발전으로 복잡한 절제술에서도 정확도와 회복 시간이 향상되고 있습니다. 또한 스텐트 삽입, 통증 관리, 영양 지원과 같은 지지요법은 전인적 치료에 필수적인 요소입니다. 전 세계 임상시험 네트워크와 실제 데이터 등록을 통해 전체 환자 집단에 대한 치료 효과에 대한 이해도가 높아지고 있습니다. 연구 자금과 산업계의 투자 증가로 담도암 치료 전망은 점차 개선되고 있으며, 그동안 제한된 선택과 나쁜 예후에 직면했던 환자 집단에 희망을 가져다주고 있습니다.

세계의 담도암 시장 성장의 원동력은?

세계의 담도암 시장 성장은 질병 발생률 증가, 진단 및 치료법 발전, 임상 연구 확대, 의료비 지출 증가 등 여러 가지 복합적인 요인에 의해 주도되고 있습니다. 세계 인구의 고령화와 비만, 바이러스성 간염, 당뇨병, 만성 염증성 질환과 같은 근본적인 위험 요인의 확산이 발병률 증가에 기여하고 있습니다. 인식의 향상과 의사의 교육으로 진단에 대한 경각심이 높아져 보다 적시에 의뢰와 병기 평가가 이루어지고 있습니다. 분자진단과 영상 진단의 기술적 발전은 정밀의료에 대한 접근을 촉진하고 동반진단과 바이오마커 검사에 대한 수요를 증가시키고 있습니다. 또한 표적치료제 및 면역항암제가 규제 당국의 승인을 획득하고, 그동안 충분히 치료받지 못했던 집단에서 임상적 가치를 입증하는 등 의약품의 혁신이 시장 확대에 기여하고 있습니다. 임상시험 참여 증가와 종양학 연구의 세계화로 인해 의약품 개발 파이프라인이 가속화되고 더 많은 지역에서 새로운 치료법에 대한 접근성이 향상되고 있습니다. 의료 시스템과 보험사들도 희귀암과 침습성 암 치료의 경제적, 임상적 중요성을 인식하고 암 인프라, 등록, 다학제적 치료팀에 대한 투자를 촉진하고 있습니다. 특히 암 발병률이 높은 아시아태평양에서는 정부 기관과 민간 단체의 암 연구 자금 지원이 증가하고 있으며, 이는 기술 혁신을 더욱 촉진하고 있습니다. 환자 옹호 활동과 온라인 지원 네트워크에 대한 접근성은 세컨드 오피니언, 첨단 의료, 임상시험 등록에 대한 수요를 증가시키고 있습니다. 이러한 모든 촉진요인은 치료 계획에 대한 실제 데이터 통합의 발전과 함께 담도암 시장의 지속적인 성장을 지원하고 있으며, 틈새 종양학 분야에서 확장 가능성과 전략적 의료 중요성이 있는 분야로 변모하고 있습니다.

부문

암 유형(간내 담관암, 간외 담관암, 담낭암), 최종사용자(병원 최종사용자, 전문 암센터 최종사용자, 외래 수술 센터 최종사용자, 기타 최종사용자)

조사 대상 기업의 예

  • Agios Pharmaceuticals
  • AstraZeneca plc
  • Basilea Pharmaceutica
  • Bayer AG
  • BeiGene Ltd.
  • Bristol Myers Squibb
  • Delcath Systems
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Incyte Corporation
  • Jazz Pharmaceuticals
  • Merck & Co., Inc.(MSD)
  • Novartis AG
  • Pfizer Inc.
  • QED Therapeutics
  • Servier Pharmaceuticals
  • Taiho Pharmaceutical Co., Ltd.
  • TransThera Sciences(Nanjing)
  • Zymeworks Inc.

AI 통합

우리는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.07.15

Global Biliary Tract Cancers Market to Reach US$778.7 Million by 2030

The global market for Biliary Tract Cancers estimated at US$625.8 Million in the year 2024, is expected to reach US$778.7 Million by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Intrahepatic Cholangiocarcinoma, one of the segments analyzed in the report, is expected to record a 3.5% CAGR and reach US$447.3 Million by the end of the analysis period. Growth in the Extrahepatic Cholangiocarcinoma segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$170.5 Million While China is Forecast to Grow at 6.8% CAGR

The Biliary Tract Cancers market in the U.S. is estimated at US$170.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$156.1 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Biliary Tract Cancers Market - Key Trends & Drivers Summarized

Why Are Biliary Tract Cancers Drawing Increasing Medical and Research Attention Worldwide?

Biliary tract cancers, which include cholangiocarcinoma, gallbladder cancer, and ampullary cancer, are drawing growing attention due to their increasing global incidence, complex diagnosis, and poor prognosis. These cancers originate in the bile ducts, gallbladder, or associated structures and are often asymptomatic until advanced stages, making early detection a persistent challenge. With limited awareness and few screening protocols in place, especially in low- and middle-income countries, the majority of patients are diagnosed at inoperable or metastatic stages. Risk factors such as primary sclerosing cholangitis, liver fluke infections, chronic biliary inflammation, and certain genetic mutations contribute to rising prevalence in both developed and emerging regions. In Southeast Asia and Latin America, endemic parasitic infections like Opisthorchis viverrini and Clonorchis sinensis are linked to elevated cholangiocarcinoma rates. Meanwhile, increasing obesity, diabetes, and metabolic syndromes are believed to be contributing to gallbladder cancer cases in Western populations. Despite its historically low profile, biliary tract cancer is now receiving more clinical focus due to its aggressive nature and the critical need for novel diagnostics and targeted therapies. The rarity and heterogeneity of these cancers also pose research challenges, necessitating greater global collaboration to understand disease mechanisms and therapeutic responses. As oncologists and health systems recognize the urgent unmet need in this space, biliary tract cancers are becoming a significant frontier in oncology, demanding more robust healthcare, policy, and research interventions.

How Are Diagnostic and Imaging Advances Transforming the Detection of Biliary Tract Cancers?

Recent advances in imaging technologies, molecular diagnostics, and biomarker research are significantly improving the detection and characterization of biliary tract cancers, although challenges remain. Traditionally, diagnosis relied on symptoms, elevated liver enzymes, and imaging techniques like ultrasound or CT scans, which often lacked sensitivity for early-stage tumors. Today, high-resolution imaging modalities such as contrast-enhanced MRI, MRCP (magnetic resonance cholangiopancreatography), and PET-CT scans provide more detailed visualization of the biliary tree, allowing better tumor localization, staging, and surgical planning. Endoscopic techniques like ERCP (endoscopic retrograde cholangiopancreatography) and endoscopic ultrasound (EUS) offer tissue sampling capabilities and enhanced diagnostic precision. The development of liquid biopsy platforms and next-generation sequencing (NGS) has opened new doors for early detection and mutation profiling, enabling more precise and individualized treatment strategies. Key biomarkers, including CA 19-9 and CEA, while nonspecific, continue to aid in monitoring disease progression when combined with imaging data. Moreover, the exploration of circulating tumor DNA (ctDNA), microRNA signatures, and methylation patterns is driving progress toward non-invasive, blood-based diagnostic tools. These tools are particularly valuable in cases where biopsies are risky or anatomically difficult. AI-enhanced imaging analytics and predictive algorithms are also emerging, offering potential in identifying subtle anomalies and reducing diagnostic delays. Although accessibility and cost remain barriers in resource-limited settings, these diagnostic innovations are steadily transforming how biliary tract cancers are detected and managed, paving the way for earlier interventions and improved patient outcomes.

What Therapeutic Advancements Are Reshaping the Treatment Landscape for Biliary Tract Cancers?

The treatment landscape for biliary tract cancers is undergoing notable transformation, driven by developments in systemic therapies, precision oncology, and surgical techniques. Historically, treatment options were limited to surgery and palliative chemotherapy, with resection offering the only potential for cure. However, fewer than 30% of patients present with resectable disease, and recurrence rates remain high. Standard chemotherapy regimens like gemcitabine and cisplatin have modest efficacy, prompting a shift toward more personalized and targeted approaches. The advent of molecular profiling has identified actionable mutations in subsets of patients, such as FGFR2 fusions, IDH1 mutations, HER2 overexpression, and MSI-high status, leading to the development of targeted therapies like pemigatinib, ivosidenib, and trastuzumab. Immunotherapy, particularly checkpoint inhibitors like pembrolizumab and nivolumab, has shown promise in MSI-high and PD-L1-positive tumors, though responses vary. Ongoing trials are investigating combination strategies to overcome resistance and improve response rates. Liver-directed therapies, including radioembolization, photodynamic therapy, and transarterial chemoembolization (TACE), are increasingly used in locally advanced cases. Advances in laparoscopic and robotic-assisted surgery have improved precision and recovery times, even in complex resections. Additionally, supportive care measures such as stenting, pain management, and nutritional support are integral to holistic care. Global clinical trial networks and real-world data registries are enhancing understanding of treatment effectiveness across patient populations. With increased research funding and industry investment, the therapeutic outlook for biliary tract cancers is gradually improving, offering hope to a patient population that has historically faced limited options and poor prognoses.

What Is Fueling the Growth in the Global Biliary Tract Cancers Market?

The growth in the global biliary tract cancers market is driven by several converging factors including rising disease incidence, advancements in diagnostics and therapies, expanding clinical research, and increasing healthcare expenditure. The aging global population and escalating prevalence of underlying risk factors-such as obesity, viral hepatitis, diabetes, and chronic inflammatory conditions-are contributing to higher case detection rates. Enhanced awareness and physician education are improving diagnostic vigilance, leading to more timely referrals and staging assessments. Technological advancements in molecular diagnostics and imaging are facilitating precision medicine approaches, thus increasing demand for companion diagnostics and biomarker testing. Moreover, pharmaceutical innovation is contributing to the market’s expansion, with targeted therapies and immuno-oncology agents gaining regulatory approvals and demonstrating clinical value in previously underserved populations. Increased participation in clinical trials and the globalization of oncology research are accelerating drug development pipelines and improving access to emerging therapies in more regions. Health systems and insurers are also recognizing the economic and clinical importance of addressing rare and aggressive cancers, prompting investments in cancer infrastructure, registries, and multidisciplinary care teams. Rising funding from government bodies and private organizations for cancer research-especially in Asia-Pacific, where disease prevalence is high-is further stimulating innovation. Patient advocacy and access to online support networks are increasing demand for second opinions, advanced care, and clinical trial enrollment. All these drivers, combined with the growing integration of real-world data into treatment planning, are supporting sustained growth in the biliary tract cancers market, transforming it from a niche oncology segment into a field of expanding potential and strategic healthcare significance.

SCOPE OF STUDY:

The report analyzes the Biliary Tract Cancers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Cancer Type (Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Gallbladder Cancer); End-Use (Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Agios Pharmaceuticals
  • AstraZeneca plc
  • Basilea Pharmaceutica
  • Bayer AG
  • BeiGene Ltd.
  • Bristol Myers Squibb
  • Delcath Systems
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Incyte Corporation
  • Jazz Pharmaceuticals
  • Merck & Co., Inc. (MSD)
  • Novartis AG
  • Pfizer Inc.
  • QED Therapeutics
  • Servier Pharmaceuticals
  • Taiho Pharmaceutical Co., Ltd.
  • TransThera Sciences (Nanjing)
  • Zymeworks Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Biliary Tract Cancers - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence and Late Diagnosis of Biliary Tract Cancers Throws the Spotlight on Unmet Clinical Needs
    • Increased Focus on Rare Oncology Segments Spurs Growth in Research and Targeted Therapy Development
    • Molecular Profiling and Biomarker Advancements Drive Adoption of Personalized Treatment Approaches
    • Here's How Immunotherapy Trials Are Reshaping the Treatment Landscape for Biliary Tract Cancers
    • Growing Pipeline of FGFR, IDH1, and HER2 Inhibitors Expands the Addressable Therapeutic Market
    • Limited Efficacy of Standard Chemotherapy Strengthens the Business Case for Novel Drug Combinations
    • Expanded Use of Genomic Testing Supports Patient Selection and Optimizes Treatment Outcomes
    • Clinical Trial Collaborations and Global Consortia Fuel Innovation and Accelerate Regulatory Timelines
    • Regulatory Incentives and Orphan Drug Designation Enhance Market Entry for Niche Therapeutics
    • Rising Healthcare Infrastructure in Emerging Markets Creates New Opportunities for Diagnostic and Treatment Access
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Biliary Tract Cancers Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Biliary Tract Cancers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Biliary Tract Cancers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Biliary Tract Cancers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Intrahepatic Cholangiocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Intrahepatic Cholangiocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Intrahepatic Cholangiocarcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Extrahepatic Cholangiocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Extrahepatic Cholangiocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Extrahepatic Cholangiocarcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Gallbladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Gallbladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Gallbladder Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Specialty Cancer Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Specialty Cancer Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Specialty Cancer Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Biliary Tract Cancers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Biliary Tract Cancers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Biliary Tract Cancers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Biliary Tract Cancers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Biliary Tract Cancers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Biliary Tract Cancers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Biliary Tract Cancers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Biliary Tract Cancers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Biliary Tract Cancers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Biliary Tract Cancers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Biliary Tract Cancers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Biliary Tract Cancers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제